Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2007 / Cilt: 15 - Sayı: 4

Current treatment strategies in deep vein thrombosis

Derin ven trombozunda güncel tedavi yaklaşımları

Pages
316–321
Publication Date
2022-09-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A timely and correct treatment approach is essential to minimize mortality and morbidity rates associated with DVT.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Venous thromboembolism or commonly known as deep venous thrombosis (DVT) is an important cause of mortality and morbidity.
📊
Key Findings & Data:In advanced age group, it has an incidence of up to 1% in developed countries.
💡
Conclusion & Impact:A timely and correct treatment approach is essential to minimize mortality and morbidity rates associated with DVT.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Venous thromboembolism or commonly known as deep venous thrombosis (DVT) is an important cause of mortality and morbidity. In advanced age group, it has an incidence of up to 1% in developed countries. Deep venous thrombosis most frequently arises from the lower extremity and pelvic veins. Since DVT can be found in about 70% of cases with pulmonary thromboembolism (PTE), and about half of the DVT cases develop PTE, these two can be regarded as a single clinicopathologic entity. The methods used in the treatment of classical DVT undergo alterations in parallel with the evolution of alternative treatment options and publication of comparative results of clinical studies. In this article, we aimed to review DVT in the light of current guidelines. A timely and correct treatment approach is essential to minimize mortality and morbidity rates associated with DVT.

Özet

Venöz tromboembolizm veya en sık görülen formuyla derin ven trombozu (DVT) önemli bir mortalite ve morbidite nedenidir. Gelişmiş ülkelerde ileri yaşlarda %1 oranında görülen bu hastalık, en sık alt ekstremite ve pelvik venlerinden kaynaklanmaktadır. Pulmoner tromboembolilerin (PTE) yaklaşık %70’inde DVT olması, DVT olgularının yarısından fazlasında PTE gelişmesi nedeniyle, bu ikisi tek bir antite olarak kabul edilebilir. Klasik DVT tedavisinde uyguladığımız yöntemler, zaman içinde yeni tedavi seçeneklerinin ortaya çıkması ve farklı klinik uygulamaların karşılaştırmalı sonuçlarının yayınlanması ile sürekli olarak değişmektedir. Bu derlemede, DVT’nin güncel kılavuz bilgileri ışığında incelenmesi amaçlandı. Zamanında ve etkin bir şekilde yapılan tedavi yaklaşımı ile DVT’den kaynaklanan mortalite ve morbiditeyi en aza indirgemek mümkündür.

🔖

Cite This Article

TANYELİ, Ö., SARIGÜL, A. (2022). Current treatment strategies in deep vein thrombosis. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 15 - Sayı: 4, 316–321. https://ajindex.com/articles/425119

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; 1:1309-12
  2. Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260-4
  3. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133-6
  4. Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154:49-56
  5. Anand SS, Bates S, Ginsberg JS, Levine M, Buller H, Prins M, et al. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 1999;159:2029-32
  6. Salzman EW, Deykin D, Shapiro RM, Rosenberg R. Management of heparin therapy: Controlled prospective trial. N Engl J Med 1975;292:1046-50
  7. Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Enoxaparin Clinical Trial Group. Ann Intern Med 2001;134:191-202
  8. Yekeler İ, Azman A, Özyazıcıoğlu A, Cerrahoğlu M, Dağ Ö. Akut vasküler tıkanmalarda fibrinolitik tedavi. Atatürk Üniversitesi Tıp Dergisi 1998;30:111 4
  9. Tünerir B, Şenel M, Beşoğul Y, Sevin B, Kural T, Aslan R. Akut derin ven trombozunun başlangıç tedavisinde streptokinaz ve heparinin karşılaştırılması. Türk Göğüs Kalp Damar Cer Derg 1998;6:240-8
  10. Lansing AM, Davis WM. Five-year follow-up study of iliofemoral venous thrombectomy. Ann Surg 1968;168:620-8
  11. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998;338:409-15
  12. Partsch H, Blattler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg 2000;32:861-9
  13. Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term